Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial

Sex Transm Dis. 2014 Jul;41(7):453. doi: 10.1097/OLQ.0000000000000152.

Authors

Vernon Mochache¹, Raymond Scott McClelland, Jennifer E Balkus

Affiliation

¹ Department of Epidemiology, University of Washington, Seattle, WA Departments of Epidemiology, Global Health, and Medicine, University of Washington, Seattle, WA Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya Vaccine and Infectious Disease Division, Fred Hutchison Cancer Research Center, Seattle, WA Department of Global Health, University of Washington, Seattle, WA jbalkus@fhcrc.org.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Infective Agents / therapeutic use*
Candidiasis, Vulvovaginal / drug therapy*
Candidiasis, Vulvovaginal / prevention & control
Chemoprevention / methods
Female
Fluconazole / therapeutic use*
Humans
Kenya
Metronidazole / therapeutic use*
Prevalence
Randomized Controlled Trials as Topic
Sex Workers*
Treatment Outcome
Trichomonas Vaginitis / drug therapy*
Trichomonas Vaginitis / prevention & control
Vaginosis, Bacterial / drug therapy*
Vaginosis, Bacterial / prevention & control

Substances

Anti-Infective Agents
Metronidazole
Fluconazole

Grants and funding